Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care

我们的目标是减少癌症死亡和与癌症治疗相关的副作用。我们设计临床试验和其他研究，同时测试几种新方法。这加快了对新疗法的评估。癌症变得越来越普遍，特别是在低收入和中等收入国家（LMIC），据估计，到2020年，70%的癌症和80%的癌症死亡将发生。我们专注于需要更实惠和有效的癌症治疗。这对高收入国家也很重要。我们测试已经用于另一种疾病的药物。这叫做再利用。我们还测试了放射治疗、手术和现有的扫描技术是否可以以不同的、更有效的方式用于改善癌症的诊断和治疗。我们还将测试新药物（免疫肿瘤学）是否可以在更短的时间内提供相同的益处和更少的副作用。未来我们将致力于：a）在LMIC中常见并导致许多死亡的癌症; B）不太常见的癌症，这使得难以进行临床试验;以及c）预防癌症的研究。在这些领域进行临床试验可能具有挑战性，并且没有多少研究小组在这些领域工作。 如果我们评估的治疗方法因我们的试验而被医生推荐给患者，我们工作的影响就会得到认可。进一步的影响是帮助提高中低收入国家的研究知名度和能力，包括帮助各国培养首席研究员。我们还从试验参与者那里收集生物样本，科学家对它们进行评估，以增加我们对癌症的了解。

Our aim is to reduce cancer deaths and the side effects associated with cancer treatments. We design clinical trials and other research studies that test several new approaches at the same time. This speeds up the evaluation of new therapies. Cancer is becoming more common, especially in low and middle income countries (LMICs) where it is estimated that 70% of cancers and 80% of cancer deaths will occur in 2020. We focus on the need for more affordable and effective cancer treatments. This is also important for high income countries. We test drugs that are already used for another disease. This is called repurposing. We also test whether radiotherapy, surgery and existing scanning techniques can be used in different and more efficient ways to improve the diagnosis and treatment of cancer. We will also test whether newer drugs (immuno–oncology) can be given for shorter periods of time with the same benefits and less side effects.In the future we will work on: a) cancers that are common and cause many deaths in LMICs; b) cancers that are less common which makes it difficult to run clinical trials; and c) studies to prevent cancer. Running a clinical trial in these areas can be challenging and not many research groups work in these areas. The impact of our work is recognised if the treatments we assess are recommended for patients by doctors because of our trials. Further impacts are to help increase research visibility and capacity in LMICs, including for example heling to develop Principal Investigators in countries. We also collect biological samples from trial participants and scientists evaluate them to increase our understanding of cancer.